Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
MIGDAL HA'EMEQ, Israel, March 16, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov as well as via the Company’s investor relations website at http://ir.enzymotec.com.
The Company will also deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Oren Bryan at [email protected].
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
Company Contact Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Contact The Ruth Group Tram Bui / Lee Roth Phone: 646-536-7035 / 7012 [email protected] [email protected]
